Oct 8 (Reuters) - U.S. Food and Drug Administration:
* FDA APPROVES FIRST TREATMENT TO INCREASE PAIN-FREE LIGHT EXPOSURE IN PATIENTS WITH A RARE DISORDER
* FDA - APPROVED SCENESSE TO INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH HISTORY OF DAMAGE TO SKIN FROM ERYTHROPOIETIC PROTOPORPHYRIA
* FDA - APPROVAL OF SCENESSE WAS GRANTED TO CLINUVEL